Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Epidemiol Infect ; 146(7): 888-894, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29633686

RESUMEN

Giardia duodenalis and Cryptosporidium spp. are common intestinal protozoa that can cause diarrhoeal disease. Although cases of infection with Giardia and Cryptosporidium have been reported in Alaska, the seroprevalence and correlates of exposure to these parasites have not been characterised. We conducted a seroprevalence survey among 887 residents of Alaska, including sport hunters, wildlife biologists, subsistence bird hunters and their families and non-exposed persons. We tested serum using a multiplex bead assay to evaluate antibodies to the Giardia duodenalis variant-specific surface protein conserved structural regions and to the Cryptosporidium parvum 17- and 27-kDa antigens. Approximately one third of participants in each group had evidence of exposure to Cryptosporidium. Prevalence of Giardia antibody was highest among subsistence hunters and their families (30%), among whom positivity was associated with lack of community access to in-home running water (adjusted prevalence ratio [aPR] 1.15, 95% confidence interval (CI) 1.02-1.28) or collecting rain, ice, or snow to use as drinking water (aPR 1.09, 95% CI 1.01-1.18). Improving in-home water access for entire communities could decrease the risk of exposure to Giardia.


Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Criptosporidiosis/epidemiología , Cryptosporidium/aislamiento & purificación , Giardia lamblia/aislamiento & purificación , Giardiasis/epidemiología , Adolescente , Adulto , Alaska/epidemiología , Antígenos de Protozoos/sangre , Criptosporidiosis/parasitología , Femenino , Giardiasis/parasitología , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Proteínas Protozoarias/sangre , Estudios Seroepidemiológicos , Adulto Joven
2.
Epidemiol Infect ; 143(6): 1236-46, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25068917

RESUMEN

We performed a study to determine rates of reinfection in three groups followed for 2 years after successful treatment: American Indian/Alaska Native (AI/AN) persons living in urban (group 1) and rural (group 2) communities, and urban Alaska non-Native persons (group 3). We enrolled adults diagnosed with H. pylori infection based on a positive urea breath test (13C-UBT). After successful treatment was documented at 2 months, we tested each patient by 13C-UBT at 4, 6, 12 and 24 months. At each visit, participants were asked about medication use, illnesses and risk factors for reinfection. We followed 229 persons for 2 years or until they became reinfected. H. pylori reinfection occurred in 36 persons; cumulative reinfection rates were 14·5%, 22·1%, and 12·0% for groups 1, 2, and 3, respectively. Study participants who became reinfected were more likely to have peptic ulcer disease (P = 0·02), low education level (P = 0·04), or have a higher proportion of household members infected with H. pylori compared to participants who did not become reinfected (P = 0·03). Among all three groups, reinfection occurred at rates higher than those reported for other US populations (<5% at 2 years); rural AI/AN individuals appear to be at highest risk for reinfection.


Asunto(s)
Infecciones por Helicobacter/epidemiología , Helicobacter pylori , Alaska/epidemiología , Escolaridad , Composición Familiar , Femenino , Infecciones por Helicobacter/tratamiento farmacológico , Infecciones por Helicobacter/etiología , Humanos , Indígenas Norteamericanos/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Recurrencia , Factores de Riesgo , Población Rural/estadística & datos numéricos , Población Urbana/estadística & datos numéricos
3.
Artículo en Inglés | MEDLINE | ID: mdl-23984273

RESUMEN

BACKGROUND: After the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in Alaska, the incidence of invasive pneumococcal disease (IPD) due to non-vaccine serotypes, particularly serotype 19A, increased. The aim of this study was to describe the molecular epidemiology of IPD due to serotype 19A in Alaska. METHODS: IPD data were collected from 1986 to 2010 through population-based laboratory surveillance. Isolates were serotyped by the Quellung reaction and MICs determined by broth microdilution. Genotypes were assessed by multilocus sequence typing. RESULTS: Among 3,294 cases of laboratory-confirmed IPD, 2,926 (89%) isolates were available for serotyping, of which 233 (8%) were serotype 19A. Across all ages, the proportion of IPD caused by serotype 19A increased from 3.5% (63/1823) pre-PCV7 (1986-2000) to 15.4% (170/1103) post-PCV7 (2001-2010) (p < 0.001); among children < 5 years of age, the proportion increased from 5.0% (39/776) to 33.0% (76/230) (p < 0.001). The annual incidence rate of IPD due to serotype 19A (all ages) increased from 0.73 cases pre-PCV7 to 2.56 cases/100,000 persons post-PCV7 (p < 0.001); rates among children < 5 years of age increased from 4.84 cases to 14.1 cases/100,000 persons (p < 0.001). Among all IPD isolates with reduced susceptibility to penicillin, 17.8% (32/180) were serotype 19A pre-PCV7 and 64% (121/189) were serotype 19A post-PCV7 (p < 0.001). Eighteen different sequence types (STs) were identified; ST199 or single locus variants of ST199 (n = 150) and ST172 (n = 59) accounted for the majority of isolates. Multidrug-resistant isolates were clustered in ST199 and ST320. CONCLUSION: While PCV13 should significantly reduce the burden of disease due to 19A, these data highlight the need to continue surveillance for IPD to monitor the effects of vaccination on the expansion and emergence of non-PCV strains.


Asunto(s)
Infecciones Neumocócicas/microbiología , Streptococcus pneumoniae/genética , Adolescente , Adulto , Factores de Edad , Alaska/epidemiología , Antibacterianos/uso terapéutico , Niño , Preescolar , Farmacorresistencia Bacteriana , Humanos , Incidencia , Pruebas de Sensibilidad Microbiana , Epidemiología Molecular , Tipificación de Secuencias Multilocus , Infecciones Neumocócicas/tratamiento farmacológico , Infecciones Neumocócicas/epidemiología , Serotipificación , Streptococcus pneumoniae/efectos de los fármacos , Adulto Joven
4.
Aliment Pharmacol Ther ; 23(8): 1215-23, 2006 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-16611283

RESUMEN

BACKGROUND: Limited information exists regarding risk factors for reinfection after cure of Helicobacter pylori infection. AIM: To determine the 2-year reinfection rate of H. pylori in a cohort of urban Alaska Natives. METHODS: Participants over 18 years of age undergoing oesophagogastroduodenoscopy had (13)C urea breath test, culture, CLOtest and histology performed. Those diagnosed with H. pylori who tested urea breath test-negative at 8 weeks after treatment were followed prospectively at 4 months, 6 months, 1 year and 2 years. Subjects experiencing H. pylori reinfection as defined by a positive urea breath test were compared with those who did not become reinfected using univariable and multivariable analysis. Risk of reinfection over time was estimated by the Kaplan-Meier method. RESULTS: Helicobacter pylori reinfection occurred in 14 of 98 subjects successfully treated. The cumulative reinfection rate was 5.1% (95% CI: 0.7%-9.5%) at 4 months, 7.2% (2.0-12.3%) at 6 months, 10.3% (4.2-16.3%) at 1-year and 14.5% (7.5-21.6%) at 2 years. In multivariable analysis, a history of previous peptic ulcer disease or presence of ulcer at time of study oesophagogastroduodenoscopy were the only risk factors associated with reinfection (P = 0.01). CONCLUSIONS: Based on the findings from our study, subjects with a history of or current peptic ulcer disease should be followed, after successful treatment for H. pylori, with periodic urea breath test to detect reinfection, as reinfection would put them at high risk for ulcer recurrence.


Asunto(s)
Infecciones por Helicobacter/diagnóstico , Helicobacter pylori , Adulto , Anciano , Alaska , Antibacterianos/uso terapéutico , Antiulcerosos/uso terapéutico , Pruebas Respiratorias , ADN Bacteriano/análisis , Farmacorresistencia Microbiana , Femenino , Estudios de Seguimiento , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/genética , Humanos , Indígenas Norteamericanos , Estilo de Vida , Masculino , Persona de Mediana Edad , Análisis Multivariante , Úlcera Péptica/complicaciones , Úlcera Péptica/tratamiento farmacológico , Estudios Prospectivos , Recurrencia , Factores de Riesgo , Población Urbana , Urea/análisis
5.
J Infect Dis ; 180(1): 41-9, 1999 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10353859

RESUMEN

Hospitalization rates for respiratory syncytial virus (RSV) infection range from 1 to 20/1000 infants. To determine the rate and severity of RSV infections requiring hospitalization for infants in the Yukon-Kuskokwim (YK) Delta of Alaska, a 3-year prospective surveillance study was conducted. The annual rate of RSV hospitalization for YK Delta infants <1 year of age was 53-249/1000. RSV infection was the most frequent cause of infant hospitalization. RSV disease severity did not differ among non-high-risk infants in the YK Delta and at Johns Hopkins Hospital (JHH). On average, 1/125 infants born in the YK Delta required mechanical ventilation for RSV infection. During the peak season, approximately $1034/child <3 years of age was spent on RSV hospitalization in the YK Delta. In YK Delta infants

Asunto(s)
Infecciones por Virus Sincitial Respiratorio/epidemiología , Factores de Edad , Alaska/epidemiología , Anticuerpos Antivirales/sangre , Baltimore/epidemiología , Preescolar , Sangre Fetal/inmunología , Hospitalización , Hospitales Comunitarios , Humanos , Incidencia , Indígenas Norteamericanos , Lactante , Recién Nacido , Inuk , Vigilancia de la Población , Estudios Prospectivos , Infecciones por Virus Sincitial Respiratorio/economía , Virus Sincitiales Respiratorios/clasificación , Factores de Riesgo , Estaciones del Año , Índice de Severidad de la Enfermedad
6.
J Orthop Sports Phys Ther ; 21(3): 172-5, 1995 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-7742843

RESUMEN

Deep friction massage (DFM) is a therapeutic modality for tendinitis, muscle strains, ligamentous sprains, and capsulitis of the trapezio-first-metacarpal joint. Depending on the stage and site of the lesion, treatment sessions may be as brief as 5 minutes or as long as 20 minutes. Many therapists find DFM to be very effective but state that treatment is very fatiguing to administer. Therapists with hypermobile fingers find it particularly difficult to perform. In order to overcome these two problems, a number of splints have been designed to treat various lesions. This article describes how to fabricate one of these splints. This splint is useful for commonly seen lesions such as supraspinatus tendinitis and a sprained acromioclavicular ligament.


Asunto(s)
Masaje/instrumentación , Masaje/métodos , Férulas (Fijadores) , Bursitis/terapia , Diseño de Equipo , Humanos , Esguinces y Distensiones/terapia , Tendinopatía/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA